Skip header and navigation

10 records – page 1 of 1.

Tumors of the Central Nervous System. Vol. 1, Gliomas, Glioblastoma (Part 1)

http://libcat.nshealth.ca/permalink/provcat40903
edited by M. A. Hayat. Springer , c2011.
Available Online
View e-Book
The most recent developments in diagnostic and therapeutic aspects of Gliomas (Glioblastoma) in the brain are presented. The importance of personalized medicine and clinical validation for targeted therapy are discussed. The identification of various types of biomarkers is included. The identification and validation of brain cancer (glioblastoma) genes are discussed. Role of cancer stem cells in the initiation, progression, and persistence of malignant gliomas is explained. The use of surgical …
Available Online
View e-Book
Other Authors
Hayat, M. A
Responsibility
edited by M. A. Hayat
Place of Publication
Dordrecht
Publisher
Springer
Date Published
c2011
Physical Description
1 online resource (xxi, 434 p.)
Series Vol.
v. 1
Series Title
Tumors of the central nervous system
ISBN
9789400703438 (print ed.)
9789400703445
Subjects (MeSH)
Antineoplastic agents - therapeutic use
Biomarkers
Brain neoplasms - diagnosis
Brain neoplasms - therapy
Glioblastoma - diagnosis
Glioblastoma - therapy
Glioma - diagnosis
Glioma - therapy
Other Subjects
; Biomedicine
Cancer Research
Neuroradiology
Neurosurgery
Oncology
Pathology
Surgery
Abstract
The most recent developments in diagnostic and therapeutic aspects of Gliomas (Glioblastoma) in the brain are presented. The importance of personalized medicine and clinical validation for targeted therapy are discussed. The identification of various types of biomarkers is included. The identification and validation of brain cancer (glioblastoma) genes are discussed. Role of cancer stem cells in the initiation, progression, and persistence of malignant gliomas is explained. The use of surgical resection, chemotherapy (e.g., temozolomide), immunotherapy, and radiotherapy for malignant glioblastoma are pointed out. Standard (established) as well as newer imaging modalities (proton magnetic resonance spectroscopy) are discussed.
Contents
Part I. Introduction -- 1. Introduction -- 2. Molecular Classification of Gliomas -- Part II. Biomarkers and Diagnosis -- 3. Glioblastoma: Endosialin Marker for Pericytes -- 4. Glioma Grading Using Cerebral Blood Volume Heterogeneity -- 5. The Role of Ectonucleotidases in Glioma Cell Proliferation -- 6. Gliomas: Role of Monoamine Oxidase B in Diagnosis -- 7. Glioma: Role of Integrin in Pathogenesis and Therapy -- 8. Proton Magnetic Resonance Spectroscopy in Intracranial Gliomas -- 9. Infiltration Zone in Glioma: Proton Magnetic Resonance Spectroscopic Imaging -- 10. Malignant Gliomas: Role of E2F1 Transcription Factor -- 11. The Role of Glucose Transporter-1 (GLUT-1) in Malignant Gliomas -- 12. Malignant Gliomas: Role of Platelet-Derived Growth Factor Receptor A (PDGFRA) -- 13. Molecular Methods for Detection of Tumor Markers in Glioblastomas -- 14. Role of MGMT in Glioblastomas -- 15. Glioblastomas: Role of CXCL12 Chemokine -- 16. Cell Death Signaling in Glioblastoma Multiforme: Role of the Bcl2L12 Oncoprotein -- 17. Glioblastoma Multiforme: Role of Polycomb Group Proteins -- 18. Glioblastoma Multiforme: Role of Cell Cycle-Related Kinase Protein (Method) -- Part III. Neural Stem Cells and Cancer Stem Cells -- 19. Markers of Stem Cells in Gliomas -- 20. Efficient Derivation and Propagation of Glioblastoma Stem-Like Cells Under Serum-Free Conditions Using the Cambridge Protocol -- 21. Glioma Cell Lines: Role of Cancer Stem Cells -- 22. Glioblastoma Cancer Stem Cells: Response to Epidermal Growth Factor Receptor Kinase Inhibitors -- Part IV. Therapy -- 23. Low- and High-Grade Gliomas: Extensive Surgical Resection -- 24. Brainstem Gangliogliomas: Total Resection and Close Follow-Up -- 25. Glioblastoma: Temozolomide-Based Chemotherapy -- 26. Drug-Resistant Glioma: Treatment with Imatinib Mesylate and Chlorimipramine -- 27. Glioblastoma Multiforme: Molecular Basis of Resistance to Erlotinib -- 28. Enhanced Glioma Chemosensitivity -- 29 Malignant Glioma Patients: Anti-Vascular Endothelial Growth Factor Monoclonal Antibody, Bevacizumab -- 30. Aggravating Endoplasmic Reticulum Stress by Combined Application of Bortezomib and Celecoxib as a Novel Therapeutic Strategy for Glioblastoma -- 31. Targeted Therapy for Malignant Gliomas -- 32. Glioblastomas: HER1/EGFR-Targeted Therapeutics -- 33. Epidermal Growth Factor Receptor Inhibition as a Therapeutic Strategy for Glioblastoma Multiforme -- 34. Role of Acyl-CoA Synthetases in Glioma Cell Survival and Its Therapeutic Implication -- 35. Malignant Glioma Patients: Combined Treatment with Radiation and Fotemustine -- 36. Malignant Glioma Immunotherapy: A Peptide Vaccine from Bench to Bedside -- 37. Malignant Glioma: Chemovirotherapy -- 38. Intracranial Glioma: Delivery of an Oncolytic Adenovirus -- 39. Use of Magnetic Resonance Spectroscopy Imaging (MRSI) in the Treatment Planning of Gliomas -- 40. Malignant Glioma Cells: Role of Trail-Induced Apoptosis -- Part V. Prognosis -- 41. Long-Term Survivors of Glioblastoma -- 42. Glioblastoma Patients: p15 Methylation as a Prognostic Factor.
Format
e-Book
thumbnail

Biomarkers of Cardiometabolic Risk, Inflammation and Disease

http://libcat.nshealth.ca/permalink/provcat39237
Filipe Palavra, Fl©vio Reis, Daniela Marado, Armando Sena, editors. Springer , c2015.
Available Online
View e-Book
Location
Online
This book discusses recent advances in the area of cardiometabolic risk biomarkers of chronic inflammatory and cardiovascular disorders. Tackling the topic in a systematic manner, the book starts with an introduction to cardiometabolic risk and its clinical relevance, comparing emergent and classical biomarkers. It then goes on to discuss cardiometabolic risk biomarkers in a range of diseases, including diabetes, ischemic stroke and neurodegenerative disorders. Biomarkers of Cardiometabolic Ris…
Available Online
View e-Book
Other Authors
Marado, Daniela
Palavra, Filipe
Reis, Fl©vio
Sena, Armando
Responsibility
Filipe Palavra, Fl©vio Reis, Daniela Marado, Armando Sena, editors
Place of Publication
Cham
Publisher
Springer
Date Published
c2015
Physical Description
1 online resource (x, 165 p. : 11 illus. in color)
ISBN
9783319160177 (print ed.)
9783319160184
Subjects (MeSH)
Biomarkers
Cardiovascular diseases - diagnosis
Inflammation
Risk factors
Other Subjects
; Medicine & Public Health
Biomedicine general
Internal Medicine
Neurology
Abstract
This book discusses recent advances in the area of cardiometabolic risk biomarkers of chronic inflammatory and cardiovascular disorders. Tackling the topic in a systematic manner, the book starts with an introduction to cardiometabolic risk and its clinical relevance, comparing emergent and classical biomarkers. It then goes on to discuss cardiometabolic risk biomarkers in a range of diseases, including diabetes, ischemic stroke and neurodegenerative disorders. Biomarkers of Cardiometabolic Risk, Inflammation and Disease is aimed at doctors specializing in internal medicine, neurology, cardiology, rheumatology, nephrology or endocrinology and will also be of interest to GPs, trainee doctors, and clinical and basic researchers working on cardiovascular and autoimmune disorders.
Contents
Inflammation biomarkers and cardiometabolic risk -- Cardiovascular disease -- Diabetes mellitus and metabolic syndrome -- Ischemic stroke -- Chronic kidney disease -- Immune-mediated inflammatory rheumatic diseases -- Cardiometabolic risk, inflammation and neurodegenerative disorders.
Format
e-Book
Location
Online
thumbnail

Cardiac Biomarkers : Case Studies and Clinical Correlations

http://libcat.nshealth.ca/permalink/provcat40319
Alan S. Maisel, Allan S. Jaffe, editors. Springer , c2016.
Available Online
View e-Book
Location
Online
This book presents a comprehensive compendium of case studies to inform clinicians how to optimally deploy the major clinically utilized biomarkers in cardiology. Biomarkers now play an integral role in the treatment and management of patients with congestive heart failure and acute ischemic heart disease because they provide crucial information about the status of individual patients. For that reason, it is important for clinicians to understand the basis for the use of these markers. Every re…
Available Online
View e-Book
Other Authors
Jaffe, Allan S
Maisel, Alan S
Responsibility
Alan S. Maisel, Allan S. Jaffe, editors
Place of Publication
Cham
Publisher
Springer
Date Published
c2016
Physical Description
1 online resource (xviii, 370 p. : 56 illus., 40 illus. in color)
ISBN
9783319429809 (print ed.)
9783319429823
Subjects (MeSH)
Biomarkers
Heart failure
Myocardial ischemia
Natriuretic Peptides - therapeutic use
Troponin - therapeutic use
Other Subjects
; Medicine & Public Health
Cardiology
Abstract
This book presents a comprehensive compendium of case studies to inform clinicians how to optimally deploy the major clinically utilized biomarkers in cardiology. Biomarkers now play an integral role in the treatment and management of patients with congestive heart failure and acute ischemic heart disease because they provide crucial information about the status of individual patients. For that reason, it is important for clinicians to understand the basis for the use of these markers. Every reader may not have the laboratory and/or clinical expertise to understand all the details associated with the use of these markers, which is why this book takes a case oriented approach and by doing so provides a practical resource to guide the clinician through the options available. Cardiac Biomarkers discusses how to use these biomarkers optimally and, in particular, how to understand when values provide actionable information. The book an essential guide for all physicians and healthcare practitioners in the field of cardiology.
Contents
[publisher supplied] The patient with chest pain: The troponin story -- Troponin Basics for the clinician -- Pathophysiology of trop I and T in myocardial ischemia/infarction -- International Definition of MI- rationale and practice -- Evaluation of patients presenting with chest pain- where do troponins fit in -- Using contemporary troponin in patients with AMI -- Using troponins to guide therapy in ACS -- Use of cTn in patients with heart failure -- Elevated cTn in other acute situations -- Use of cTn for detection of more chronic disease states -- High sensitivity assays- what are they and why do we need them -- Use of troponin for the evaluation of patients potentially at risk for cardiovascular disease -- Gaps in our biomarker armamentarium: what novel biomarkers might be synergistic in patients with acute disease -- The patient with shortness of breath: the natriuretic peptide story -- Evaluation of patients presenting with sob- where do nps fit in -- Pathophysiology of bnp, and ntpro bnp -- A clinicians guide to lab assays for nps -- Using NPS in the ED- diagnosis -- Using NPs in the ED- algorithms and risk stratification -- Using NPs in the hospital -- NPs at the time of discharge -- Finger stick NP levels at home -- Guiding therapy of heart failure with NPs -- Caveats to NP measurement -- Other biomarkers for heart failure -- Biomarkers of cardiorenal disease -- Biomarkers of cardiac risk.
Format
e-Book
Publication Type
Case Reports
Location
Online
thumbnail

Advances in Salivary Diagnostics

http://libcat.nshealth.ca/permalink/provcat39442
Charles F. Streckfus, editor. Springer , c2015.
Available Online
View e-Book
Location
Online
This book reviews the progress made in salivary diagnostics and identifies the likely direction of future endeavors. After an introductory section describing the histological and anatomical features of the salivary glands and salivary function, salivary collection devices and diagnostic platforms are reviewed. The field of "salivaomics" is then considered in detail, covering, for example, proteomics, the peptidome, DNA and RNA analysis, biomarkers, and methods for biomarker discovery. Salivary …
Available Online
View e-Book
Other Authors
Streckfus, Charles F
Responsibility
Charles F. Streckfus, editor
Place of Publication
Berlin, Heidelberg
Publisher
Springer
Date Published
c2015
Physical Description
1 online resource (xiii, 204 p. : 48 illus., 38 illus. in color)
ISBN
9783662453988 (print ed.)
9783662453995
Subjects (MeSH)
Biomarkers
Clinical chemistry tests
Pathologic Processes - diagnosis
Saliva - physiology
Salivary Glands
Other Subjects
; Dentistry
Dentistry
General Practice / Family Medicine
Laboratory Medicine
Abstract
This book reviews the progress made in salivary diagnostics and identifies the likely direction of future endeavors. After an introductory section describing the histological and anatomical features of the salivary glands and salivary function, salivary collection devices and diagnostic platforms are reviewed. The field of "salivaomics" is then considered in detail, covering, for example, proteomics, the peptidome, DNA and RNA analysis, biomarkers, and methods for biomarker discovery. Salivary diagnostics for oral and systemic diseases are thoroughly discussed, and the role of salivary gland tissue engineering for future diagnostics is explored. The book closes by considering legal issues and barriers to salivary diagnostic development. Advances in Salivary Diagnostics will be an informative and stimulating reference for both practitioners and students.
Contents
1 Introduction -- 2 The History of Salivary Diagnostics -- 3 Saliva Collection Devices and Diagnostic Platforms -- 4 Salivary Omics -- 5 Salivary Diagnostics and the Oral Microbiome -- 6 Development of Nanoparticle- Enabled Protein Biomarker Discovery: Implementation for Saliva-Based Traumatic Brain Injury Detection -- 7 Saliva Diagnostics for Oral Diseases -- 8 Salivary Gland Tissue Engineering and Future Diagnostics -- 9 Using Saliva Secretions to Model Disease Progression.
Format
e-Book
Location
Online
thumbnail

Pan-cancer Integrative Molecular Portrait Towards a New Paradigm in Precision Medicine

http://libcat.nshealth.ca/permalink/provcat39380
Christophe Le Tourneau, Maud Kamal, editors. (1st ed.) Springer , c2015.
Available Online
View e-Book
Location
Online
This original book provides readers with an overview of the latest developments in personalized medicine clinical trials in oncology. The topics covered range from the rationale behind this new generation of clinical trials and the latest statistical models for high-throughput molecular techniques, bioinformatics, high-throughput screening molecular techniques and the challenges entailed by implementing them in daily practice. It also covers the key role of pathology in the validation of molecu…
Available Online
View e-Book
Other Authors
Kamal, Maud
Le Tourneau, Christophe
Responsibility
Christophe Le Tourneau, Maud Kamal, editors
Edition
1st ed.
Place of Publication
Cham
Publisher
Springer
Date Published
c2015
Physical Description
1 online resource (x, 144 p. : 100 illus., 50 illus. in color)
ISBN
9783319221885 (print ed.)
9783319221892
Subjects (MeSH)
Biomarkers
Clinical Trial
Neoplasms - genetics
Precision Medicine
Other Subjects
Cancer Research
Medicine & Public Health
Molecular Medicine
Oncology
Pathology
Abstract
This original book provides readers with an overview of the latest developments in personalized medicine clinical trials in oncology. The topics covered range from the rationale behind this new generation of clinical trials and the latest statistical models for high-throughput molecular techniques, bioinformatics, high-throughput screening molecular techniques and the challenges entailed by implementing them in daily practice. It also covers the key role of pathology in the validation of molecular results and the complex assessment of predictive biomarkers. The different topics covered are supplemented by unique concrete examples based on the SHIVA trial. The authors are all members of the French Curie Institute, one of the world's foremost cancer research institutions.
Contents
Introduction: Rationale for Precision Medicine Clinical Trials -- The Key Role of Pathology in the Context of Precision Medicine Trials -- Basis for Molecular Genetics in Cancer -- Microarrays-Based Molecular Profiling to Identify Genomic Alterations -- High Throughput Technologies: DNA and RNA Sequencing Strategies and Potential -- Bioinformatics for Precision Medicine in Oncology -- Assessment of Biomarkers' Predictive Value of Efficacy -- Designs for Evaluating Precision Medicine Trials -- Conclusions and Perspectives: Challenges for the Clinical Implementation of Precision Medicine Trials.
Format
e-Book
Location
Online
thumbnail

Murine Models, Energy Balance, and Cancer

http://libcat.nshealth.ca/permalink/provcat39257
Nathan A. Berger, editor. Springer , c2015.
Available Online
View e-Book
Location
Online
This volume provides a transdisciplinary and translational review of many of the leading murine models used to study the mechanisms, mediators and biomarkers linking energy balance to cancer. It provides a review of murine models that should be of interest to basic, clinical and applied research investigators as well as nutrition scientists and students that work in cancer prevention, cancer control and treatment. The worldwide obesity pandemic has been extensively studied by epidemiologic and …
Available Online
View e-Book
Other Authors
Berger, Nathan A
Responsibility
Nathan A. Berger, editor
Place of Publication
Cham
Publisher
Springer
Date Published
c2015
Physical Description
1 online resource (xv, 295 p. : 40 illus., 36 illus. in color)
Series Vol.
10
Series Title
Energy balance and cancer
ISBN
9783319167329 (print ed.)
9783319167336
ISSN
2199-2622
Subjects (MeSH)
Biomarkers
Disease models, animal
Energy metabolism
Mice
Neoplasms - etiology
Obesity - complications
Other Subjects
Animal Models
Biomedicine
Cancer Research
Laboratory Medicine
Abstract
This volume provides a transdisciplinary and translational review of many of the leading murine models used to study the mechanisms, mediators and biomarkers linking energy balance to cancer. It provides a review of murine models that should be of interest to basic, clinical and applied research investigators as well as nutrition scientists and students that work in cancer prevention, cancer control and treatment. The worldwide obesity pandemic has been extensively studied by epidemiologic and observational studies and even, in some cases, by randomized controlled trials. However, the development and control of obesity, its comorbidities and its impact on cancer usually occurs over such long periods that it is difficult, if not impossible to conduct randomized controlled trials in humans to investigate environmental contributions to obesity, energy balance and their impact on cancer. In contrast, model organisms, especially mice and rats, provide valuable assets for performing these studies under rigorously controlled conditions and in sufficient numbers to provide statistically significant results. In this volume, many of the leading and new murine models used to study the mechanisms and mediators linking cancer with obesity, sleep, exercise, their modification by environment and how they may continue to be used to further elucidate these relations as well as to explore preclinical aspects of prevention and/or therapeutic intervention are considered. This volume provides an important compilation and analysis of major experimental systems and principles for further preclinical research with translational impact on energy balance and cancer.
Contents
Relevance of Circadian Rhythm in Cancer -- Environmental Manipulation and Neuropeptide Effects on Energy Balance and Cancer -- The MRL Mouse: A Model of Regeneration and Cancer -- Living Large: What Mouse Models Reveal about Growth Hormone and Obesity -- Mouse Models to Study Obesity Effects on Hematologic Malignancies -- Energy Balance, IGF-1 and Cancer: Causal Lessons from Genetically Engineered Mice -- Mouse Models to Study Leptin in Breast Cancer Stem Cells -- Mouse Models used to study the effects of Diabetes, Insulin and IGFs on cancer -- Impact of Energy Balance on Chemically Induced Mammary Carcinogenesis in a Rat -- Models and Mechanisms of High Fat Diet Promotion of Pancreatic Cancer -- Maternal energetics and the developmental origins of prostate cancer in offspring -- Mouse Models to Study the Effect of Natural Products on Obesity-Associated NAFLD/NASH -- Mouse Models to Study Metformin Effects in Carcinogenesis.
Format
e-Book
Location
Online
thumbnail

Tumors of the Central Nervous System. Vol. 2, Gliomas, Glioblastoma (Part 2)

http://libcat.nshealth.ca/permalink/provcat40904
edited by M.A. Hayat. Springer , c2011.
Available Online
View e-Book
Advantages and limitations of biomarkers in gliomagenesis are described. Molecular subtypes of gliomas are detailed. The role played by TP53 gene mutation in the deadliest brain tumor, glioblastoma multiforme, is pointed out. The role of mutations of IDH1 and IDH2, and isocitrate dehydrogenases in malignant gliomas are presented. Metabolic differences in different regions of the glioma tumor are clarified. Various types of imaging modalities, including PET and SPECT, to diagnose gliomas in gene…
Available Online
View e-Book
Other Authors
Hayat, M.A
Responsibility
edited by M.A. Hayat
Place of Publication
Dordrecht
Publisher
Springer
Date Published
c2011
Physical Description
1 online resource (xxi, 458 p.)
Series Vol.
v. 2
Series Title
Tumors of the central nervous system
ISBN
9789400706170 (print ed.)
9789400706187
Subjects (MeSH)
Antineoplastic agents - therapeutic use
Biomarkers
Brain neoplasms - diagnosis
Brain neoplasms - therapy
Glioblastoma - diagnosis
Glioblastoma - therapy
Glioma - diagnosis
Glioma - therapy
Other Subjects
; Biomedicine
Cancer Research
Neuroradiology
Neurosurgery
Oncology
Pathology
Surgery
Abstract
Advantages and limitations of biomarkers in gliomagenesis are described. Molecular subtypes of gliomas are detailed. The role played by TP53 gene mutation in the deadliest brain tumor, glioblastoma multiforme, is pointed out. The role of mutations of IDH1 and IDH2, and isocitrate dehydrogenases in malignant gliomas are presented. Metabolic differences in different regions of the glioma tumor are clarified. Various types of imaging modalities, including PET and SPECT, to diagnose gliomas in general and glioblastoma in particular in patients are explained in detail. Both low-grade and high-grade gliomas are discussed. Conventional as well as fluorescent-guided resection techniques for high-grade, recurrent malignant gliomas are detailed. Impact of resection extent on outcomes in patients with high-grade gliomas is clarified. The advantage of the use of intraoperative low-field MRI in glioma surgery is explained.
Contents
1. Introduction -- Part I. Biomarkers and Diagnosis -- 2. Gliomagenesis: Advantages and Limitations of Biomarkers -- 3. Molecular Subtypes of Gliomas -- 4. Glioblastoma: Germline Mutation of TP53 -- 5. Familial Gliomas: Role of TP53 Gene -- 6. The Role of IDH1 and IDH2 Mutations in Malignant Gliomas -- 7. Malignant Glioma: Isocitrate Dehydrogenases 1 and 2 Mutations -- 8. Metabolic Differences in Different Regions of Glioma Samples -- 9. Glioblastoma Patients: Role of Methylated MGMT -- 10. Brain Tumor Angiogenesis and Glioma Grading: Role of Tumor Blood Volume and Permeability Estimates Using Perfusion CT -- 11. Vasculogenic Mimicry in Glioma -- 12. Newly Diagnosed Glioma: Diagnosis Using Positron Emission Tomography with Methionine and Fluorothymidine -- 13. Role of Diffusion Tensor Imaging in Differentiation of Glioblastomas from Solitary Brain Metastases -- 14. 131I-TM-601 SPECT imaging of Human Glioma -- 15. Assessment of Biological Target Volume Using Positron Emission Tomography in High-Grade Glioma Patients -- 16. Skin Metastases of Glioblastoma -- Part II. Therapy -- 17. Diffuse Low-Grade Gliomas: What Does “Complete Resection” Mean? -- 18. Quantitative Approach of the Natural Course of Diffuse Low-Grade Gliomas -- 19. Impact of Extent of Resection on Outcomes in Patients with High-Grade Gliomas -- 20. Glioma Surgery: Intraoperative Low Field Magnetic Resonance Imaging -- 21. Low-Grade Gliomas: Intraoperative Electrical Stimulations -- 22. Malignant Gliomas: Present and Future Therapeutic Drugs -- 23. Recurrent Malignant Glioma Patients: Treatment with Conformal Radiotherapy and Systemic Therapy -- 24 Glioblastoma: Boron Neutron Capture Therapy -- 25. Glioblastoma: Anti-tumor Action of Cyclosporin A and Functionally Related Drugs -- 26. Glioblastoma Patients: Chemotherapy with Cisplatin, Temozolomide and Thalidomide -- 27. Glioblastoma: Role of Galectin-1 in Chemoresistance -- 28. Glioma-Initiating Cells: Interferon Treatment -- 29. Glioblastoma: Anti-tumor Action of Natural and Synthetic Cannabinoids -- 30. Patients with Recurrent High-Grade Glioma: Therapy with Combination of Bevacizumab and Irinotecan --- 31. Monitoring Gliomas In Vivo Using Diffusion-Weighted MRI During Gene Therapy-Induced Apoptosis -- 32. High-Grade Gliomas: Dendritic Cell Therapy -- 33. Glioblastoma Multiforme: Use of Adenoviral Vectors -- 34. Fischer/F98 Glioma Model: Methodology -- 35. Cellular and Molecular Characterization of Anti-VEGF and IL-6 Therapy in Experimental Glioma -- 36. Adult Brainstem Gliomas: Diagnosis and Treatment -- 37. The Use of Low Molecular Weight Heparin in the Treatment and Prevention of Thromboembolic Disease in Glioma Patients -- Part III. Prognosis -- 38. Brainstem Gliomas: An Overview -- 39. Tumor-Associated Epilepsy in Patients with Glioma -- 40. Brain Tumors Arising in the Setting of Chronic Epilepsy -- 41. Low-Grade Gliomas: Role of Relative Cerebral Blood Volume in Malignant Transformation -- 42. Angiocentric Glioma-Induced Seizures: Lesionectomy.
Format
e-Book
thumbnail

MicroRNAs and Other Non-Coding RNAs in Inflammation

http://libcat.nshealth.ca/permalink/provcat39169
Catherine M. Greene, editor. Springer , c2015.
Available Online
View e-Book
Location
Online
The book serves as a comprehensive resource for scientists and clinicians studying the role of non-coding RNAs in inflammation (viral infections, wound inflammation), human inflammatory diseases (i.e. rheumatoid arthritis, Crohn's disease, diabetes), and innate immunity. It provides a universal reference work comprising both basic and specialized information. Given that ncRNAs represent new therapeutic targets, this volume will also be of interest to industrial biomedical researchers and those …
Available Online
View e-Book
Other Authors
Greene, Catherine M
Responsibility
Catherine M. Greene, editor
Place of Publication
Cham
Publisher
Springer
Date Published
c2015
Physical Description
1 online resource (x, 237 p. : 17 illus., 16 illus. in color)
Series Title
Progress in inflammation research
ISBN
9783319136882 (print ed.)
9783319136899
Subjects (MeSH)
Biomarkers
Inflammation - genetics
MicroRNAs - genetics
RNA, Long Noncoding - genetics
Other Subjects
Biomedicine
Cell Biology
Gene Expression
Immunology
Molecular Medicine
Abstract
The book serves as a comprehensive resource for scientists and clinicians studying the role of non-coding RNAs in inflammation (viral infections, wound inflammation), human inflammatory diseases (i.e. rheumatoid arthritis, Crohn's disease, diabetes), and innate immunity. It provides a universal reference work comprising both basic and specialized information. Given that ncRNAs represent new therapeutic targets, this volume will also be of interest to industrial biomedical researchers and those involved in drug development.
Contents
The biology of microRNA -- The biology of long non-coding RNA -- microRNA regulation of neutrophil function -- How non-coding RNAs contribute to macrophage polarization -- Endogenous control of dendritic cell activation by miRNA -- Noncoding RNA expression during viral infection: the long and the short of it -- Wound inflammation: emerging role of miRNA -- The importance of microRNAs in rheumatoid arthritis -- MicroRNAs with impact on adipose tissue inflammation in obesity -- The relationship between miR-29, NOD2 and Crohn's disease -- The role of ncRNA in diabetes -- ncRNA as diagnostics and prognostics for hepatocellular carcinoma.
Format
e-Book
Location
Online
thumbnail

Post-Traumatic Arthritis : Pathogenesis, Diagnosis and Management

http://libcat.nshealth.ca/permalink/provcat38931
Steven A. Olson, MD, Farshid Guilak, PhD, editors. Springer US , c2015.
Available Online
View e-Book
Location
Online
Bringing together the most up-to-date research on post-traumatic arthritis (PTA) and its management, this book is a comprehensive presentation of the current thinking on all aspects of the mechanisms of joint injury and subsequent development of PTA. Divided into thematic sections, it includes discussions of the incidence and burden of PTA, both in society at large and in the military population specifically; the relevant experimental work on PTA, from basic science to animal models; peri-artic…
Available Online
View e-Book
Other Authors
Guilak, PhD, Farshid
Olson, MD, Steven A
Responsibility
Steven A. Olson, MD, Farshid Guilak, PhD, editors
Place of Publication
Boston, MA
Publisher
Springer US
Date Published
c2015
Physical Description
1 online resource (xx, 360 p. : 98 illus., 65 illus. in color)
ISBN
9781489976055 (print ed.)
9781489976062
Subjects (MeSH)
Biomarkers
Cartilage, Articular - pathology
Joint Deformities, Acquired - therapy
Osteoarthritis - diagnosis
Osteoarthritis - etiology
Osteoarthritis - therapy
Other Subjects
Medicine & Public Health
Orthopedics
Rheumatology
Sports Medicine
Abstract
Bringing together the most up-to-date research on post-traumatic arthritis (PTA) and its management, this book is a comprehensive presentation of the current thinking on all aspects of the mechanisms of joint injury and subsequent development of PTA. Divided into thematic sections, it includes discussions of the incidence and burden of PTA, both in society at large and in the military population specifically; the relevant experimental work on PTA, from basic science to animal models; peri-articular tissue responses to joint injury and potential mechanisms of PTA; the current clinical assessment and treatment of common joint injuries leading to PTA; and emerging technologies and treatments for PTA, including biomarkers and stem cell therapies. Taken together, it will be an invaluable resource for orthopedic surgeons, rheumatologists and other joint injury researchers and clinicians.
Contents
Section I: The Problem of Post-Traumatic Arthritis -- Arthritis that Develops after Joint Injury: Is it Post-Traumatic Arthritis or Post-Traumatic OsteoArthritis? -- Post-Traumatic Arthritis: Definitions and Burden of Disease -- Arthritis after Joint Injury: The Military Experience -- Section II: Experimental Models of Joint Injury -- In Vitro Cartilage Explant Injury Models -- Animal Models of Meniscal Injury in Post-Traumatic Arthritis -- Anterior Cruciate Transection/Disruption Models of Posttraumatic Arthritis -- Closed Joint ACL Disruption Murine Model of PTA -- Whole Joint Models of Articular Injury and Articular Fracture -- Instability: Dynamic Loading Models -- Survey of Animal Models in Post-Traumatic Arthritis: Choosing the Right Model to Answer the Right Question -- Section III: Peri-articular Tissue Response to Joint Injury -- The Response of Cartilage to Injury -- The Response of the Subchondral Bone to Injury -- Genetic Variability in the Response to Injury -- Aging and Post-Traumatic Arthritis -- Potential Mechanisms of PTA: Cell Death -- Potential Mechanisms of PTOA: Inflammation -- Potential Mechanisms of PTA: Oxidative Stress -- Potential Mechanisms of PTA: Alterations in Joint Loading -- Section IV: Clinical Assessment and Treatment of Patients with Joint Injury -- Imaging Specific to Cartilage Injury -- Outcomes of ACL Injury: The MOON Consortium -- Current Treatment and Outcomes of Intra-articular Fractures -- Non-arthroplasty Treatments for PTA in the Lower Extremity -- Results of Arthroplasty in Post-Traumatic Arthritis -- Section V: Developing and Future Assessment and Therapies -- Measurement of Severity of Injury after Articular Fracture and Correlation with Post-Traumatic Arthritis Development -- Biomarkers of PTA -- Potential Targets for Pharmacologic Therapies for Prevention of PTA -- Stem Cell Therapies for Post-Traumatic Arthritis -- Unanswered Questions and Future Directions in Post-Traumatic Arthritis.
Format
e-Book
Location
Online
thumbnail

Understanding Suicide : From Diagnosis to Personalized Treatment

http://libcat.nshealth.ca/permalink/provcat40000
Philippe Courtet, editor. (1st ed.) Springer , c2016.
Available Online
View e-Book
Location
Online
In this book international experts address a range of key current issues relating to suicide. The opening chapters discuss nosology, definitions, clinical determinants, and conceptual models of the suicide process and consider the evidence regarding potential biomarkers of suicide risk based on neuroscientific research. Adopting a neo-Durkheimian perspective, the role of various social factors in the genesis of suicidal behavior is then explored in depth. Practical user-friendly tools that faci…
Available Online
View e-Book
Other Authors
Courtet, Philippe
Responsibility
Philippe Courtet, editor
Edition
1st ed.
Place of Publication
Cham
Publisher
Springer
Date Published
c2016
Physical Description
1 online resource (xi, 457 p. : 11 illus., 10 illus. in color)
ISBN
9783319262802 (print ed.)
9783319262826
Subjects (MeSH)
Biomarkers
Precision Medicine - methods
Socioeconomic factors
Suicide - prevention & control
Suicide - psychology
Other Subjects
; Medicine & Public Health
Clinical Psychology
Psychiatry
Abstract
In this book international experts address a range of key current issues relating to suicide. The opening chapters discuss nosology, definitions, clinical determinants, and conceptual models of the suicide process and consider the evidence regarding potential biomarkers of suicide risk based on neuroscientific research. Adopting a neo-Durkheimian perspective, the role of various social factors in the genesis of suicidal behavior is then explored in depth. Practical user-friendly tools that facilitate risk assessment by clinicians are provided, and detailed consideration is given to efficient and innovative strategies for the prevention of suicide and the treatment of suicidal behavior, such as psychotherapy, psychopharmacological approaches, and effective organization of care, including surveillance and the use of online tools. The final part of the book focuses on the need for and development of a personalized approach within the field of suicide prevention. Understanding Suicide will be of interest to psychiatrists, psychologists, mental health professionals, general practitioners, researchers in suicidology, and students.
Contents
Part I. Diagnostic and Clinical issues -- 1. Nomenclature and Definition of Suicidal Behavior -- 2. A Modern Semiology of Suicidal Behavior -- 3. Asking about Suicide as Suicide Prevention: The Columbia Suicide Severity Rating Scale (C-SSRS) -- 4. Temperament in Suicidal Behaviour -- 5. The Addiction to Suicidal Behavior -- 6. Suicidal Crisis in the Digital Age -- Part II. Biomarkers of Suicide (Advances in Biology of Suicide) -- 7. Biomarkers of Suicide: Predicting the Predictable? -- 8. Genetics and Suicide -- 9. Epigenetics -- 10. Neuroinflammation in Suicide -- 11. A Social Neuroscience Perspective on Suicidal Behavior -- 12. Psychological and Social Pain -- 13. Biochemical Markers -- 14. Translational Research in Suicide: Is It Possible to Study Suicide in Animal Models? -- Part III. Neo-Durkheimian View: From Society to Groups at Risk -- 15. Effect of Economic Crises on Suicide Rates -- 16. Key Features of Suicidal Behavior in Mental Disorders -- 17. How to Deal with Personality in Suicidal Behavior? -- 18. How Japan Reduced Suicides: A Law That Changed Society–The Japanese Model -- 19. The Challenge to Survive in Jail -- 20. Racism and Discrimination, Killers? -- 21. Why It Is Important to Talk About Religion -- Part IV. Treatments of Suicidal Behaviour (and Related Traits) -- 22. Surveillance Is a Powerful Tool to Prevent Suicidal Acts -- 23. Preventing Suicidality Through Online Tools: The SUPREME Project -- 24. Antidepressants and Suicide Risk: A Challenge -- 25. Lithium: The Key Antisuicide Agent -- 26. Antipsychotics -- 27. Psychological Interventions in Suicide -- 28. Advocacy Organisations -- Part V. A Need for Personalized Suicidology -- 29. Childhood Maltreatment -- 30. Family Risk Factors for Suicidal Behavior: Opportunities for Early Identification and Intervention -- 31. The Gender Matters -- 32. A Need for Personalised Suicidology: Pharmacoepidemiology -- 33. Pharmacogenetic Studies of Suicide: Potential Relevance of Main Polymorphic CYPs and ABCB1 -- 34. Monitoring, Evaluation, and Referral of Patients with Suicide Risk Upon Hospital Admission.
Format
e-Book
Location
Online
thumbnail

10 records – page 1 of 1.

Revise Search

Narrow By